4539.T Stock - Nippon Chemiphar Co., Ltd.
Unlock GoAI Insights for 4539.T
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $32.57B | $30.75B | $31.56B | $32.51B | $31.54B |
| Gross Profit | $8.75B | $7.74B | $8.19B | $9.07B | $11.44B |
| Gross Margin | 26.9% | 25.2% | 25.9% | 27.9% | 36.3% |
| Operating Income | $607.00M | $-494,000,000 | $-241,000,000 | $825.00M | $564.00M |
| Net Income | $294.00M | $-180,000,000 | $339.00M | $700.00M | $495.00M |
| Net Margin | 0.9% | -0.6% | 1.1% | 2.2% | 1.6% |
| EPS | $81.48 | $-49.88 | $93.92 | $194.09 | $137.69 |
Nippon Chemiphar Co., Ltd., together with its subsidiaries, manufactures, markets, imports, exports, and sells, ethical pharmaceuticals and diagnostic agents in Japan and internationally. It offers diagnostic products, such as IgE NC, a diagnostic kit that provides results and reveals total IgE levels, as well as 57 individual allergen reagents; and DP3000, a device for allergen-specific IgE measurements. The company also develops NC-2400, a PPAR-delta agonist; NC-2500, a novel advanced xanthine oxidoreductase inhibitor for the treatment of hyperuricemia/gout; and NC-2600, a P2X4 receptor antagonist for the treatment of neuropathic pain. In addition, it develops NC-2700, a novel urate transporter 1 inhibitor that enhance excretion urate to urine; NC-2800, a delta opioid receptor agonist for the treatment of depression/anxiety; Uralyt-U, an alkalization therapeutic drug; Soleton, an analgesic and anti-inflammatory drug; and Calvan, a hypertension therapeutic drug. Further, the company provides quasi-drugs, nutrients, health foods, cosmetics, and various type of creams. It distributes its generic pharmaceuticals through wholesalers to hospitals and pharmacies. The company was formerly known as Hitachi Chemical Co., Ltd. and changed its name to Nippon Chemiphar Co., Ltd. in 1970. Nippon Chemiphar Co., Ltd. was founded in 1950 and is headquartered in Tokyo, Japan.
Visit WebsiteEarnings History & Surprises
4539.TEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Oct 31, 2025 | — | $-17.74 | — | — |
Q3 2025 | Aug 4, 2025 | — | $62.92 | — | — |
Q2 2025 | May 14, 2025 | — | $71.79 | — | — |
Q1 2025 | Jan 29, 2025 | — | $21.90 | — | — |
Q4 2024 | Oct 31, 2024 | — | $-47.12 | — | — |
Q3 2024 | Jul 31, 2024 | — | $34.92 | — | — |
Q2 2024 | May 13, 2024 | — | $-78.70 | — | — |
Q1 2024 | Jan 31, 2024 | — | $20.23 | — | — |
Q4 2023 | Oct 31, 2023 | — | $-13.30 | — | — |
Q3 2023 | Jul 31, 2023 | — | $21.89 | — | — |
Q2 2023 | May 12, 2023 | — | $-95.59 | — | — |
Q1 2023 | Jan 31, 2023 | — | $-58.74 | — | — |
Q4 2022 | Oct 31, 2022 | — | $67.32 | — | — |
Q3 2022 | Jul 29, 2022 | — | $180.90 | — | — |
Q2 2022 | May 13, 2022 | — | $-69.80 | — | — |
Q1 2022 | Jan 31, 2022 | — | $200.53 | — | — |
Q4 2021 | Oct 29, 2021 | — | $66.75 | — | — |
Q3 2021 | Jul 30, 2021 | — | $-3.62 | — | — |
Q2 2021 | May 14, 2021 | — | $44.51 | — | — |
Q1 2021 | Jan 29, 2021 | — | $164.68 | — | — |
Latest News
Frequently Asked Questions about 4539.T
What is 4539.T's current stock price?
What is the analyst price target for 4539.T?
What sector is Nippon Chemiphar Co., Ltd. in?
What is 4539.T's market cap?
Does 4539.T pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to 4539.T for comparison